Search Results

Neutron Therapeutics, a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced that its compact accelerator has received final acceptance for use at the University of Birmingham’s High Flux Accelerator-Driven Neutron Facility.

United Therapeutics Corporation, a public benefit corporation, announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics’ common stock.

Excellos Inc., a cell therapy contract and development manufacturing organization, announced it had taken additional investment to accelerate commercialization efforts.

Daicel Arbor Biosciences is excited to announce the release of the next generation of its myTXTL® kits, for cell-free protein expression, designed to simplify and accelerate antibody discovery and protein engineering.

Laser Photonics Corporation announced today that it is attending and sponsoring this year’s Acceleration Summit: National Center for Manufacturing Sciences (NCMS) Technology Showcase.

GENFIT announced the achievement of a historic corporate milestone: the U.S. Food and Drug Administration accelerated approval of Iqirvo1 2 80 mg tablets – as unveiled today by Ipsen – as a first-in-class treatment for PBC in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

Collegium Pharmaceutical, Inc. announced that it has entered into an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock.

Accelerated Biosciences Corp. (“Accelerated Bio”) is excited to announce a strategic partnership with Agathos Biologics aimed at developing ethically derived cell lines from Accelerated Bio’s human Trophoblast Stem Cells (“hTSC”) for manufacturing complex biologics.

The Foundation for Angelman Syndrome Therapeutics (FAST) announced the establishment of an associated drug development accelerator called AS2Bio Inc.

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024.